Updated Jul 16, 2026
Thompson Peter A. has filed 9 SEC Form 4 filings across 4 companies in the last 90 days — selling. Lifetime open-market sales: $60.57M.
Peter A. Thompson is a corporate insider involved with Sionna Therapeutics, Inc. and Corvus Pharmaceuticals, Inc. He holds the position of Director and is a 10% owner in these companies, contributing to their strategic direction and governance.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-09 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 85.9K | $44.86 | $3.85M |
| 2026-07-02 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 115.8K | $45.50 | $5.27M |
| 2026-05-30 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 101 | $44.49 | $4K |
| 2026-05-11 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 184.6K | $46.22 | $8.53M |
| 2026-05-11 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 59.8K | $44.58 | $2.66M |
| 2026-05-11 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 48.5K | $44.61 | $2.17M |
| 2026-04-22 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 2.9K | $44.52 | $131K |
| 2026-04-22 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 52.4K | $44.68 | $2.34M |
| 2026-04-16 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 226.9K | $45.34 | $10.29M |
| 2026-04-16 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 235.9K | $44.64 | $10.53M |
| 2026-04-16 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 47.8K | $44.51 | $2.13M |
| 2026-02-05 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 29.1K | $44.58 | $1.30M |
| 2026-02-05 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 1.9K | $44.57 | $84K |
| 2026-01-30 | CRVS | Corvus Pharmaceuticals, Inc. | M — Option exercise | 15.0K | $2.12 | $32K |
| 2026-01-30 | CRVS | Corvus Pharmaceuticals, Inc. | M — Option exercise | 15.0K | $1.64 | $25K |
| 2026-01-30 | CRVS | Corvus Pharmaceuticals, Inc. | M — Option exercise | 15.0K | $2.49 | $37K |
| 2026-01-30 | CRVS | Corvus Pharmaceuticals, Inc. | M — Option exercise | 15.0K | $0.96 | $14K |
| 2026-01-30 | CRVS | Corvus Pharmaceuticals, Inc. | M — Option exercise | 15.0K | $0.99 | $15K |
| 2026-01-30 | CRVS | Corvus Pharmaceuticals, Inc. | M — Option exercise | 15.0K | $2.60 | $39K |
| 2026-01-30 | CRVS | Corvus Pharmaceuticals, Inc. | M — Option exercise | 15.0K | $2.74 | $41K |
Peter A. Thompson is a corporate insider involved with Sionna Therapeutics, Inc. and Corvus Pharmaceuticals, Inc. He holds the position of Director and is a 10% owner in these companies, contributing to their strategic direction and governance.…
9 primary Form 4 filings in the last 90 days, covering 4 companies.
Recorded transactions: 0 open-market purchases () and 21 open-market sales ($60.57M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Thompson Peter A. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.